Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOMERICA INCBMRA · Entity 8171 | Director | December 13, 2024 | December 18, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOMERICA INC
Report date December 13, 2024 · Filed December 18, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 156,000 |
Reported balance
After 2024-12-13 transaction · row 1
1 source rowRow 1 · 2024-12-13 · Grant · Acquired 85,000 · Balance 156,000 F1: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of December 13, 2024, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of December 13, 2024, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 13, 2024 Filed Dec 18, 2024 00:30 UTC | BIOMERICA INC BMRA · Entity 8171 | GrantCommon stock | 85,000 | $0.31 | $26,350.00 |
DisclosureSEC source: 0001493152-24-050502 · ownership.xml · nonDerivative · entry 1 Emerson Jane · CIK 0001398437 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,000 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of December 13, 2024, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. Read SEC document |
| December 13, 2023 Filed Dec 14, 2023 22:10 UTC | BIOMERICA INC BMRA · Entity 8171 | GrantNon-qualified stock option · Derivative | 75,000 | Not disclosed Strike: $1.01 | Not disclosed |
DisclosureSEC source: 0001493152-23-044910 · ownership.xml · derivative · entry 2 Emerson Jane · CIK 0001398437 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2034-12-13 F1 · shares: Options granted to Ms. Coste as part of her Fiscal 2024 Board compensation package. F2 · price: Not Applicable Read SEC document |
| April 20, 2023 Filed Dec 11, 2023 22:19 UTC | BIOMERICA INC BMRA · Entity 8171 | GrantNon-qualified stock option · Derivative | 32,000 | Not disclosed Strike: $1.67 | Not disclosed |
DisclosureSEC source: 0001493152-23-044433 · ownership.xml · derivative · entry 2 Emerson Jane · CIK 0001398437 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2033-04-20 F1 · shares: Options granted to Ms. Emerson in April 2023 as part of her fiscal 2023 Board compensation package. Final issuance was subject to and conditioned upon the approval by stockholders of the 2023 Stock Incentive Plan, which occured on December 7, 2023. F2 · price: Not Applicable Read SEC document |
| December 09, 2021 Filed Dec 10, 2021 22:35 UTC | BIOMERICA INC BMRA · Entity 8171 | GrantNon-qualified stock option · Derivative | 25,000 | Not disclosed Strike: $4.46 | Not disclosed |
DisclosureSEC source: 0001513162-21-000146 · primary_doc.xml · derivative · entry 2 Emerson Jane · CIK 0001398437 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 25,000 shares Expires 2031-12-09 F1 · price: Not applicable Read SEC document |
| December 10, 2020 Filed Dec 12, 2020 01:08 UTC | BIOMERICA INC BMRA · Entity 8171 | GrantNon-qualified stock option · Derivative | 20,000 | Not disclosed Strike: $6.36 | Not disclosed |
DisclosureSEC source: 0001513162-20-000239 · primary_doc.xml · derivative · entry 2 Emerson Jane · CIK 0001398437 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 20,000 shares Expires 2030-12-10 F1 · price: Not applicable Read SEC document |
| December 19, 2019 Filed Dec 23, 2019 21:19 UTC | BIOMERICA INC BMRA · Entity 8171 | GrantNon Qualified Stock Option · Derivative | 30,000 | Not disclosed Strike: $2.81 | Not disclosed |
DisclosureSEC source: 0001513162-19-000257 · primary_doc.xml · derivative · entry 2 Emerson Jane · CIK 0001398437 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 30,000 shares Expires 2029-12-20 F1 · price: Not applicable. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 22:48 UTC | BIOMERICA INC BMRA · Entity 8171 | GrantNon Qualified Stock Option · Derivative | 35,000 | Not disclosed Strike: $2.25 | Not disclosed |
DisclosureSEC source: 0001513162-18-000321 · primary_doc.xml · derivative · entry 2 Emerson Jane · CIK 0001398437 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 35,000 shares Expires 2028-12-20 F1 · price: Not applicable Read SEC document |
| October 05, 2018 Filed Oct 10, 2018 20:49 UTC | BIOMERICA INC BMRA · Entity 8171 | OtherNon Qualified Stock Option · Derivative | 25,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001513162-18-000256 · primary_doc.xml · derivative · entry 2 Emerson Jane · CIK 0001398437 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 25,000 shares Expires 2018-10-30 F1 · price: Consists of various options reported previously with varying dates and prices, both expiring and excerisable. F1 · balance_after: Consists of various options reported previously with varying dates and prices, both expiring and excerisable. Read SEC document |
| October 05, 2018 Filed Oct 10, 2018 20:49 UTC | BIOMERICA INC BMRA · Entity 8171 | Exercise / conversionCommon Stock | 25,000 | $0.75 | $18,750.00 |
DisclosureSEC source: 0001513162-18-000256 · primary_doc.xml · nonDerivative · entry 1 Emerson Jane · CIK 0001398437 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2018 Filed Jan 24, 2018 23:03 UTC | BIOMERICA INC BMRA · Entity 8171 | GrantNon qualified stock option · Derivative | 25,000 | Not disclosed Strike: $3.90 | Not disclosed |
DisclosureSEC source: 0001513162-18-000026 · primary_doc.xml · derivative · entry 2 Emerson Jane · CIK 0001398437 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 25,000 shares Expires 2028-01-22 F2 · price: Not applicable. F1 · derivative.exercise_date: Exercisable 01/22/2019. Read SEC document |
| January 05, 2017 Filed Jan 6, 2017 18:07 UTC | BIOMERICA INC BMRA · Entity 8171 | OtherNon-qualified stock option · Derivative | 25,000 | Not disclosed Strike: $0.43 | Not disclosed |
DisclosureSEC source: 0001513162-17-000009 · primary_doc.xml · derivative · entry 2 Emerson Jane · CIK 0001398437 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 25,000 shares Expires 2017-01-05 F1 · price: Consists of various options with varying dates and prices, both expiring and exercisable Read SEC document |
| January 05, 2017 Filed Jan 6, 2017 18:07 UTC | BIOMERICA INC BMRA · Entity 8171 | Exercise / conversionCommon Stock | 25,000 | $0.43 | $10,750.00 |
DisclosureSEC source: 0001513162-17-000009 · primary_doc.xml · nonDerivative · entry 1 Emerson Jane · CIK 0001398437 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 16:44 UTC | BIOMERICA INC BMRA · Entity 8171 | PurchaseCommon Stock | 1,000 | $2.80 | $2,803.90 |
DisclosureSEC source: 0001513162-16-001018 · primary_doc.xml · nonDerivative · entry 1 Emerson Jane · CIK 0001398437 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.